-
Amgen's DMab scores in trials
财富中文网 2009-07-10 11:42For the biotech, a new drug for bone cancer and osteoporosis could mean a big boost in revenue.By Alyssa AbkowitzAn Amgen trial drug -- called denosum...
-
安进新药DMab在试验中获得成功
Alyssa Abkowitz 2009-07-10 11:41对于安进这家生物技术公司而言，一种治疗骨癌和骨质疏松症的新药可能使其收入大大增加。作者：Alyssa Abkowitz安进（Amgen）的一种试用药物——名为狄诺塞麦(denosumab)——于7月7日达到新的里程碑，这家生物技术公司宣布了该药物针对骨癌的最新临床试验结果。对2000多名患者的试验显...
-
Eli Lilly's patent problem
Shelley DuBois 2010-08-24 01:54In 2009, Eli Lilly CEO John Lechleiter introduced a new drug development strategy called the Development Center of Excellence. The center's mission is...
-
Cisco's 'earth-shattering' announcement
Michael V. Copeland 2010-03-10 07:33For all you folks who had dreams of flying cars or Cisco (CSCO) announcing the purchase of EMC, what CEO John Chambers revealed Tuesday after weeks of...
-
Tim Geithner's latest headache
财富中文网 2009-07-16 11:27The treasury secretary's bid to rein in derivatives meets skepticism.By Carol J. LoomisThe Obama Administration has given itself two months to tell Co...
-
It's a phone! It's a browser! It's a wallet?
财富中文网 2009-11-09 05:41By Jessica ShamboraWill your cellphone soon become a proxy for your credit card? Zong and others are betting on it.If there’s one thing online merchan...
-
What's so great about working at Goldman?
Scott Cendrowski 2011-01-31 06:01The past 12 months have undoubtedly had Goldman Sachs (GS, Fortune 500) wishing for an invisibility cloak. The bank was sued by the SEC for trading ac...
-
Amazon's newest Kindle takes aim at newspapers
财富中文网 2009-05-08 02:07Amazon hopes to convert readers of magazines and newspapers to its newest e-book reader, the Kindle DX.By Jessica ShamboraThe question of whether Amaz...
-
科技业下一波浪潮：当大数据遇上生物学
ERIKA FRY，SY MUKHERJEE 2018-03-29 05:30去年12月，CVS提出以690亿美元收购安进保险公司。今年1月，又有三大巨头——亚马逊、摩根大通和伯克谢尔哈撒韦表示要成立合资公司，降低共100万左右员工的医疗成本并提高效果。之后3月，信诺保险表示将出资超过500亿美元收购医药福利管理机构Express Scripts。为何近来医疗领域交易如此热闹...
-
制药巨头抱团能圆发财梦吗？
Jen Wieczner 2014-02-17 07:46三年前，美国卫生部门官员曾建议大型制药公司共同开发治疗药物而不是相互竞争，当时这些公司的反应很矛盾。毕竟，大型制药公司是竞争最激烈而且自我保护力度极大的领域之一。这些企业为本公司药品的方方面面都申请了专利；对于侵害自己利益的对手，它们会予以回击；专利到期后，为了阻挡竞争者，它们会发起价格战。但现在，...
